HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today released an update to its recent announcements pertaining to the acquisition of clinics and companies worldwide that have developed and are developing protocols for the care of late stage cancer patients using a variety of immunotherapy treatments.
Ron Howell, President and CEO of HST Global, Inc. stated “HST is committed to the acquisition and development of Health and Wellness Centers that exhibit success with immunotherapy therapies. Alternative therapies are achieving extraordinary degrees of success, as demonstrated by companies such as Dendreon Corporation (NASDAQ: DNDN) whose immunotherapy prostate-cancer drug Provenge was found to extend survival rates.”
HST’s recent announcement to acquire Bryomed International (www.bryomed.net) is the next phase of the company’s overall strategic plan. The pending acquisition involves a family of immunotherapy products that include over 8,000 completed Case Studies and have been registered for the treatment of patients as an adjunct therapy before, during and after traditional cancer treatments. The 20 million dollar cash, stock and royalty Agreement will secure the exclusive worldwide rights to ten (10) existing and all future Immunotherapy products. These products have been registered by the respective Government Health Agencies in the CA-4 Nations (Guatemala, Honduras, Nicaragua and El Salvador) and Belize. Additionally, one (1) of the existing products has qualified for registration with the United States Food and Drug Administration (FDA) for use as a prescription based, NDC registered product.
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.